Hualan Biological Bacterin IncSHE 301207 Stock Report

Hualan Biological Bacterin Inc. engages in vaccine and related medical supplies production. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.